Distinguished in Attention Deficit Hyperactivity Disorder (ADHD)

Marina Danckaerts

Leuven, VLG, BE 
Distinguished in Attention Deficit Hyperactivity Disorder (ADHD)
Leuven, VLG, BE 
OverviewLocationsClinical Research

Overview

Marina Danckaerts practices in Leuven, Belgium. Ms. Danckaerts is rated as a Distinguished expert by MediFind in the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Her top areas of expertise are Attention Deficit Hyperactivity Disorder (ADHD), Transient Tic Disorder, Acute Lymphoblastic Leukemia (ALL), and Ehlers-Danlos Syndrome (EDS).

Her clinical research consists of co-authoring 75 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 46 articles and participated in 1 clinical trial in the study of Attention Deficit Hyperactivity Disorder (ADHD).

Gender
Female

Locations

Leuven, VLG, Belgium
Other Locations
Gent, VLG, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 4, Multicenter, 2-part Study Composed of a Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity Disorder
A Phase 4, Multicenter, 2-part Study Composed of a Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: September 08, 2025
Intervention Type: Drug, Other
Study Drugs: Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride
Study Phase: Phase 4

75 Total Publications

Correction: Effectiveness of a cognitive-behavioral sleep hygiene intervention for adolescents with ADHD: a randomized controlled trial.
Correction: Effectiveness of a cognitive-behavioral sleep hygiene intervention for adolescents with ADHD: a randomized controlled trial.
Journal: European child & adolescent psychiatry
Published: August 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Danckaerts's expertise for a condition
ConditionClose
      View All 7 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile